​

CVS Health (CVS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CVS Stock Forecast

CVS Health stock forecast is as follows: an average price target of $73.50 (represents a 65.69% upside from CVS’s last price of $44.36) and a rating consensus of 'Buy', based on 25 wall street analysts offering a 1-year stock forecast.

CVS Price Target

The average price target for CVS Health (CVS) is $73.50 based on 1-year price targets from 25 Wall Street analysts in the past 3 months, with a price target range of $86.00 to $66.00. This represents a potential 65.69% upside from CVS's last price of $44.36.

CVS Analyst Ratings

Buy

According to 25 Wall Street analysts, CVS Health's rating consensus is 'Buy'. The analyst rating breakdown for CVS stock is 0 'Strong Buy' (0.00%), 14 'Buy' (56.00%), 10 'Hold' (40.00%), 1 'Sell' (4.00%), and 0 'Strong Sell' (0.00%).

CVS Health Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 03, 2024George HillDeutsche Bank$66.00$59.0811.71%48.78%
Nov 18, 2024Stephen BaxterWells Fargo$66.00$57.1115.57%48.78%
Oct 24, 2024Ann HynesMizuho Securities$66.00$57.0415.71%48.78%
Oct 21, 2024David MacDonaldTruist Financial$76.00$58.2030.60%71.33%
Oct 21, 2024Jessica TassanPiper Sandler$72.00$59.1521.72%62.31%
Oct 10, 2024Andrew MokBarclays$82.00$66.6323.07%84.85%
Aug 08, 2024George HillDeutsche Bank$63.00$57.858.90%42.02%
Jun 28, 2024Brian AbrahamsRBC Capital$74.00$58.5826.33%66.82%
Jun 28, 2024Lisa GillJ.P. Morgan$86.00$58.5846.82%93.87%
Jun 20, 2024Andrew MokBarclays$65.00$61.016.54%46.53%
May 02, 2024Anton HieRBC Capital$68.00$56.3120.76%53.29%
Mar 15, 2024Jessica TassanPiper Sandler$94.00$77.4021.45%111.90%
Dec 12, 2023Erin WrightMorgan Stanley$100.00$73.7635.57%125.43%
Sep 13, 2023David MacdonaldTruist Financial$98.00$70.5238.97%120.92%
Sep 12, 2023Justin LakeWolfe Research$80.00$70.5213.44%80.34%
Jul 12, 2023David MacdonaldTruist Financial$103.00$71.2744.52%132.19%
Jan 13, 2023Morgan Stanley$120.00$89.1834.56%170.51%
Jan 03, 2023Wells Fargo$101.00$92.918.71%127.68%
Jan 03, 2023Evercore ISI$100.00$93.197.31%125.43%
Nov 23, 2022Morgan Stanley$119.00$100.2218.74%168.26%
Sep 07, 2022Evercore ISI$125.00$100.5224.35%181.79%
Aug 15, 2022Mizuho Securities$120.00$106.3912.79%170.51%
Aug 14, 2022George HillDeutsche Bank$120.00$106.3912.79%170.51%
Aug 08, 2022Credit Suisse$117.00$102.2614.41%163.75%
Aug 04, 2022UBS$127.00$103.1423.13%186.29%
May 05, 2022Deutsche Bank$113.00$97.7315.62%154.73%
Apr 11, 2022Ivan FeinsethTigress Financial$125.00$104.4519.67%181.79%
Feb 21, 2022George HillDeutsche Bank$110.00$102.137.71%147.97%
Feb 13, 2022Matt BorschBMO Capital$120.00$104.2415.12%170.51%
Feb 09, 2022Ben HendrixRBC Capital$119.00$104.7913.56%168.26%
Feb 09, 2022Nathan RichGoldman Sachs$121.00$104.7915.47%172.77%
Jan 20, 2022Brian TanquilutJefferies$120.00$102.3917.20%170.51%
Jan 16, 2022Michael ChernyBank of America Securities$117.00$106.2210.15%163.75%
Jan 11, 2022Lance WilkesBernstein$116.00$105.489.97%161.50%
Jan 06, 2022Steve BaxterWells Fargo$111.00$102.048.78%150.23%
Jan 05, 2022David S MacdonaldTruist Financial$124.00$105.2517.81%179.53%
Dec 13, 2021Ricky GoldwasserMorgan Stanley$125.00$98.3727.07%181.79%
Dec 10, 2021A.J. RiceCredit Suisse$120.00$98.3322.04%170.51%
Dec 10, 2021Charles RhyeeCowen & Co.$114.00$98.3315.94%156.99%
Dec 01, 2021Joseph FranceSeaport Global$110.00$88.3124.56%147.97%
Nov 11, 2021Kevin CaliendoUBS$106.00$93.7113.11%138.95%
Nov 03, 2021Steven HalperCantor Fitzgerald$115.00$95.8320.00%159.24%
May 19, 2021Justin LakeWolfe Research$93.00$87.696.06%109.65%

The latest CVS Health stock forecast, released on Dec 03, 2024 by George Hill from Deutsche Bank, set a price target of $66.00, which represents a 11.71% increase from the stock price at the time of the forecast ($59.08), and a 48.78% increase from CVS last price ($44.36).

CVS Health Price Target by Period

1M3M12M
# Anlaysts2612
Avg Price Target$66.00$71.33$73.17
Last Closing Price$44.36$44.36$44.36
Upside/Downside48.78%60.80%64.95%

In the current month, the average price target of CVS Health stock is $66.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 48.78% increase as opposed to CVS Health's last price of $44.36. This month's average price target is down -7.47% compared to last quarter, and down -9.80% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 18, 2024Wells FargoBuyOverweightUpgrade
Oct 23, 2024Wells FargoBuyBuyHold
Oct 23, 2024RBC CapitalUnderperformUnderperformHold
Oct 21, 2024Piper SandlerOverweightOverweightHold
Oct 11, 2024Cowen & Co.BuyBuyHold
Oct 10, 2024BarclaysEqual-WeightOverweightUpgrade
Oct 08, 2024Evercore ISIOutperformOutperformHold
Oct 04, 2024Cowen & Co.HoldBuyUpgrade
Oct 01, 2024Wells FargoEqual-WeightEqual-WeightHold
Oct 01, 2024RBC CapitalUnderperformUnderperformHold
Oct 01, 2024Deutsche BankHoldHoldHold
Sep 20, 2024RBC CapitalSector PerformSector PerformHold
Sep 20, 2024BarclaysEqual-WeightEqual-WeightHold
Sep 10, 2024RBC CapitalUnderperformUnderperformHold
Sep 10, 2024Wells FargoEqual-WeightEqual-WeightHold
Sep 06, 2024RBC CapitalOutperformOutperformHold
Aug 12, 2024BarclaysEqual-WeightEqual-WeightHold
Aug 12, 2024Wells FargoEqual-WeightEqual-WeightHold
Aug 08, 2024Deutsche BankHoldHoldHold
Aug 08, 2024Cantor FitzgeraldNeutralNeutralHold
Jul 23, 2024UBSUnderperformUnderperformHold
Jul 23, 2024Wells FargoMarket PerformMarket PerformHold
Jul 08, 2024Zacks Investment ResearchOutperformOutperformHold
Jun 28, 2024Argus ResearchBuyBuyHold
Jun 20, 2024BarclaysEqual-WeightEqual-WeightHold
May 30, 2024UBSUnderperformUnderperformHold
May 30, 2024Wells FargoMarket PerformMarket PerformHold
May 07, 2024Cowen & Co.Market PerformHoldDowngrade
May 02, 2024HSBCUnderperformHoldDowngrade
May 02, 2024SVB LeerinkUnderperformUnderperformHold
May 02, 2024Wells FargoMarket PerformMarket PerformHold
May 02, 2024RBC CapitalOutperformOutperformHold
May 02, 2024Bank of America SecuritiesBuyBuyHold
Apr 04, 2024RBC CapitalEqual-WeightEqual-WeightHold
Apr 04, 2024Raymond JamesUnderperformUnderperformHold
Mar 15, 2024RBC CapitalBuyBuyHold
Mar 15, 2024Piper SandlerUnderperformUnderperformHold
Feb 26, 2024Leerink PartnersUnderperformUnderperformHold
Feb 08, 2024HSBCUnderperformUnderperformHold
Feb 08, 2024RBC CapitalBuyBuyHold
Jan 30, 2024Morgan StanleyEqual-WeightEqual-WeightHold
Dec 27, 2023Piper SandlerNeutralNeutralHold
Dec 27, 2023RBC CapitalOutperformOutperformHold
Dec 22, 2023Morgan StanleyUnderperformUnderperformHold
Dec 22, 2023RBC CapitalBuyBuyHold
Dec 12, 2023Morgan StanleyOverweightOverweightHold
Dec 12, 2023Raymond JamesOutperformOutperformHold
Sep 19, 2023B. Riley SecuritiesBuyInitialise
Sep 19, 2023BarclaysOverweightInitialise
Sep 19, 2023Goldman SachsNeutralInitialise
Sep 19, 2023JefferiesHoldInitialise
Sep 19, 2023CitigroupNeutralInitialise
Sep 19, 2023Morgan StanleyOverweightEqual-WeightInitialise
Sep 19, 2023Cowen & Co.Market PerformInitialise
Sep 19, 2023CJS SecuritiesMarket OutperformInitialise
Sep 19, 2023JMP SecuritiesMarket PerformInitialise
Sep 13, 2023Raymond JamesOutperformOutperformHold
Sep 12, 2023Wolfe ResearchOutperformUpgrade
Aug 28, 2023SVB LeerinkMarket PerformMarket PerformHold
Aug 10, 2023Wells FargoEqual-WeightEqual-WeightHold
Aug 10, 2023BernsteinMarket PerformMarket PerformHold
Jul 12, 2023Wells FargoEqual-WeightOverweightUpgrade
Apr 21, 2023Cantor FitzgeraldOverweightInitialise
Jan 13, 2023Morgan StanleyOverweightOverweightHold
Jan 12, 2023Evercore PartnersReduceDowngrade
Jan 03, 2023Wells FargoEqual-WeightEqual-WeightHold
Sep 07, 2022Evercore ISIOutperformOutperformHold
Sep 07, 2022Mizuho SecuritiesBuyBuyHold
Aug 14, 2022Deutsche BankHoldHoldHold
Aug 08, 2022Credit SuisseOutperformOutperformHold
Aug 04, 2022UBSBuyBuyHold
May 03, 2022Tigress FinancialBuyBuyHold
Feb 21, 2022Deutsche BankBuyBuyHold
Feb 13, 2022BMO CapitalMarket PerformMarket PerformHold
Jan 12, 2022BernsteinOutperformOutperformHold
Dec 18, 2021Morgan StanleyOverweightOverweightHold
Aug 08, 2021Deutsche BankBuyBuyHold

CVS Health's last stock rating was published by Wells Fargo on Nov 18, 2024. The company Upgrade its CVS rating from "Buy" to "Overweight".

CVS Health Financial Forecast

CVS Health Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$93.81B$89.76B$88.92B$85.28B$83.85B$81.16B$80.64B$76.83B$76.60B$73.79B$72.62B$69.10B$69.55B$67.06B$65.34B$66.75B$66.89B$64.81B
Avg Forecast$105.50B$104.97B$100.23B$97.52B$100.63B$99.14B$95.09B$92.81B$97.17B$92.75B$91.41B$89.33B$90.58B$88.30B$86.41B$80.69B$76.43B$76.74B$76.41B$75.54B$75.66B$70.52B$70.24B$68.36B$68.73B$66.62B$64.00B$64.08B$63.93B$63.02B
High Forecast$108.11B$107.56B$102.70B$99.92B$103.11B$101.59B$97.44B$94.77B$98.76B$92.94B$91.41B$89.33B$93.15B$89.97B$88.54B$82.68B$78.32B$76.74B$76.41B$75.54B$75.66B$70.52B$70.24B$68.36B$68.73B$66.62B$64.00B$64.08B$63.93B$63.02B
Low Forecast$103.09B$102.57B$97.93B$95.28B$98.33B$96.87B$92.92B$90.45B$92.82B$92.56B$91.41B$89.33B$87.84B$85.13B$84.43B$78.84B$74.68B$76.74B$76.41B$75.54B$75.66B$70.52B$70.24B$68.36B$68.73B$66.62B$64.00B$64.08B$63.93B$63.02B
# Analysts64464379137548191898811151799101110101099
Surprise %------------1.04%1.02%1.03%1.06%1.10%1.06%1.06%1.02%1.01%1.05%1.03%1.01%1.01%1.01%1.02%1.04%1.05%1.03%

CVS Health's average Quarter revenue forecast for Mar 24 based on 4 analysts is $89.33B, with a low forecast of $89.33B, and a high forecast of $89.33B. CVS's average Quarter revenue forecast represents a -4.78% decrease compared to the company's last Quarter revenue of $93.81B (Dec 23).

CVS Health EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137548191898811151799101110101099
EBITDA------------$3.37B$3.69B$3.23B$4.82B$3.77B$4.87B$5.70B$4.59B$2.18B$3.89B$5.50B$4.75B$3.03B$3.66B$5.82B$4.59B$4.17B$3.97B
Avg Forecast$5.84B$5.81B$5.55B$5.40B$5.57B$5.49B$5.26B$5.14B$5.38B$5.13B$5.06B$5.37B$5.01B$4.89B$4.78B$4.88B$2.35B$4.83B$4.80B$4.44B$4.76B$4.43B$4.42B$3.87B$4.32B$4.19B$4.02B$3.80B$4.02B$3.96B
High Forecast$5.98B$5.95B$5.68B$5.53B$5.71B$5.62B$5.39B$5.25B$5.47B$5.14B$5.06B$6.44B$5.16B$4.98B$4.90B$5.86B$2.82B$4.83B$4.80B$5.32B$4.76B$4.43B$4.42B$4.64B$4.32B$4.19B$4.02B$4.56B$4.02B$3.96B
Low Forecast$5.71B$5.68B$5.42B$5.27B$5.44B$5.36B$5.14B$5.01B$5.14B$5.12B$5.06B$4.29B$4.86B$4.71B$4.67B$3.90B$1.88B$4.83B$4.80B$3.55B$4.76B$4.43B$4.42B$3.09B$4.32B$4.19B$4.02B$3.04B$4.02B$3.96B
Surprise %------------0.67%0.76%0.68%0.99%1.61%1.01%1.19%1.03%0.46%0.88%1.25%1.23%0.70%0.87%1.45%1.21%1.04%1.00%

4 analysts predict CVS's average Quarter EBITDA for Mar 24 to be $5.37B, with a high of $6.44B and a low of $4.29B. This is 59.16% upper than CVS Health's previous annual EBITDA (Dec 23) of $3.37B.

CVS Health Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137548191898811151799101110101099
Net Income------------$2.05B$2.26B$1.90B$2.14B$2.30B$-3.41B$2.95B$2.31B$1.30B$1.60B$2.78B$2.22B$973.00M$1.22B$2.98B$2.01B$1.75B$1.53B
Avg Forecast$2.03B$2.40B$2.36B$1.97B$1.69B$2.14B$2.18B$1.70B$1.29B$1.81B$2.19B$2.71B$2.51B$2.68B$2.66B$2.46B$1.40B$2.51B$2.75B$2.24B$2.32B$2.25B$2.60B$1.81B$1.56B$1.67B$2.41B$1.66B$2.12B$2.23B
High Forecast$2.10B$2.48B$2.44B$2.03B$1.74B$2.21B$2.25B$2.05B$1.98B$1.87B$2.19B$3.25B$2.54B$2.78B$2.75B$2.95B$1.68B$2.51B$2.75B$2.68B$2.35B$2.25B$2.60B$2.17B$1.56B$1.67B$2.41B$1.99B$2.12B$2.23B
Low Forecast$1.97B$2.33B$2.29B$1.91B$1.64B$2.07B$2.12B$1.57B$552.50M$1.74B$2.18B$2.17B$2.48B$2.53B$2.59B$1.97B$1.12B$2.51B$2.75B$1.79B$2.29B$2.25B$2.60B$1.45B$1.56B$1.67B$2.41B$1.33B$2.12B$2.23B
Surprise %------------0.82%0.84%0.71%0.87%1.65%-1.36%1.07%1.03%0.56%0.71%1.07%1.23%0.62%0.73%1.24%1.21%0.82%0.69%

CVS Health's average Quarter net income forecast for Mar 24 is $2.71B, with a range of $2.17B to $3.25B. CVS's average Quarter net income forecast represents a 32.28% increase compared to the company's last Quarter net income of $2.05B (Dec 23).

CVS Health SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137548191898811151799101110101099
SG&A------------------------------
Avg Forecast-----------------$9.39B$9.35B$9.24B$9.26B$8.63B$8.60B$8.37B$8.41B$8.15B$7.83B$7.84B$7.82B$7.71B
High Forecast-----------------$9.39B$9.35B$9.24B$9.26B$8.63B$8.60B$8.37B$8.41B$8.15B$7.83B$7.84B$7.82B$7.71B
Low Forecast-----------------$9.39B$9.35B$9.24B$9.26B$8.63B$8.60B$8.37B$8.41B$8.15B$7.83B$7.84B$7.82B$7.71B
Surprise %------------------------------

CVS Health's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CVS last annual SG&A of $NaN (undefined).

CVS Health EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts64464379137548191898811151799101110101099
EPS------------$1.59$1.76$1.48$1.66$1.76$-2.59$2.25$1.76$0.98$1.21$2.11$1.69$0.74$0.93$2.27$1.54$1.34$1.17
Avg Forecast$1.61$1.91$1.88$1.57$1.34$1.70$1.73$1.35$1.02$1.44$1.74$1.70$1.99$2.13$2.12$2.10$1.92$2.00$2.18$2.17$1.85$1.79$2.07$1.73$1.24$1.33$1.91$1.62$1.68$1.77
High Forecast$1.67$1.97$1.94$1.62$1.38$1.75$1.79$1.63$1.57$1.49$1.74$1.76$2.02$2.21$2.18$2.17$1.94$2.00$2.18$2.17$1.87$1.79$2.07$1.73$1.24$1.33$1.91$1.62$1.68$1.77
Low Forecast$1.57$1.85$1.82$1.52$1.30$1.65$1.68$1.25$0.44$1.39$1.73$1.63$1.97$2.01$2.05$2.04$1.91$2.00$2.18$2.17$1.82$1.79$2.07$1.73$1.24$1.33$1.91$1.62$1.68$1.77
Surprise %------------0.80%0.83%0.70%0.79%0.92%-1.30%1.03%0.81%0.53%0.68%1.02%0.98%0.60%0.70%1.19%0.95%0.80%0.66%

According to 4 Wall Street analysts, CVS Health's projected average Quarter EPS for Mar 24 is $1.70, with a low estimate of $1.63 and a high estimate of $1.76. This represents a 6.63% increase compared to CVS previous annual EPS of $1.59 (Dec 23).

CVS Health Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
CVSCVS Health$44.04$73.5066.89%Buy
CICigna$265.59$400.0050.61%Buy
ELVElevance Health$366.30$542.1448.00%Buy
CNCCentene$57.81$81.5040.98%Buy
UNHUnitedHealth Group$485.52$618.7527.44%Buy
HUMHumana$233.89$292.1324.90%Hold
MOHMolina Healthcare$291.78$347.0018.93%Hold
ALHCAlignment Healthcare$10.83$10.00-7.66%Buy

CVS Forecast FAQ

Is CVS Health a good buy?

Yes, according to 25 Wall Street analysts, CVS Health (CVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 14 'Buy' recommendations, accounting for 56.00% of CVS's total ratings.

What is CVS's price target?

CVS Health (CVS) average price target is $73.5 with a range of $66 to $86, implying a 65.69% from its last price of $44.36. The data is based on 25 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will CVS Health stock go up soon?

According to Wall Street analysts' prediction for CVS stock, the company can go up by 65.69% (from the last price of $44.36 to the average price target of $73.5), up by 93.87% based on the highest stock price target, and up by 48.78% based on the lowest stock price target.

Can CVS Health stock reach $70?

CVS's average twelve months analyst stock price target of $73.5 supports the claim that CVS Health can reach $70 in the near future.

What is CVS Health's current price target trend?

2 Wall Street analysts forecast a $66 price target for CVS Health (CVS) this month, up 48.78% from its last price of $44.36. Compared to the last 3 and 12 months, the average price target increased by 60.80% and increased by 64.95%, respectively.

What are CVS Health's analysts' financial forecasts?

CVS Health's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $387.68B (high $396.91B, low $378.57B), average EBITDA is $21.46B (high $21.97B, low $20.95B), average net income is $7.71B (high $8.25B, low $7.4B), average SG&A $0 (high $0, low $0), and average EPS is $6.12 (high $6.55, low $5.88). CVS's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $408.22B (high $418.3B, low $398.88B), average EBITDA is $22.59B (high $23.15B, low $22.08B), average net income is $8.76B (high $9.05B, low $8.5B), average SG&A $0 (high $0, low $0), and average EPS is $6.96 (high $7.19, low $6.75).

Did the CVS's actual financial results beat the analysts' financial forecasts?

Based on CVS Health's last annual report (Dec 2023), the company's revenue was $357.78B, beating the average analysts forecast of $345.97B by 3.41%. Apple's EBITDA was $13.74B, missing the average prediction of $19.56B by -29.75%. The company's net income was $8.34B, missing the average estimation of $10.31B by -19.11%. Apple's SG&A was $0, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $6.49, missing the average prediction of $8.34 by -22.20%. In terms of the last quarterly report (Dec 2023), CVS Health's revenue was $93.81B, beating the average analysts' forecast of $90.58B by 3.57%. The company's EBITDA was $3.37B, missing the average prediction of $5.01B by -32.72%. CVS Health's net income was $2.05B, missing the average estimation of $2.51B by -18.36%. The company's SG&A was $0, beating the average forecast of $0 by 0%. Lastly, the company's EPS was $1.59, missing the average prediction of $1.99 by -20.13%